Evaluation of lipid profiles in patients treated with capecitabine

SÜRMELİOĞLU N., PAYDAŞ S., KARATAŞ Y., SEYDAOĞLU G.

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.47, no.4, pp.1206-1209, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.3906/sag-1607-53
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1206-1209
  • Keywords: Capecitabine, triglycerides, cholesterol, INDUCED SEVERE HYPERTRIGLYCERIDEMIA, OF-THE-LITERATURE, CHEMOTHERAPY
  • Çukurova University Affiliated: Yes

Abstract

Background/aim: Capecitabine is a prodrug of 5-fluorouracil and has shown significant antitumor activity. The main adverse effects are hand-foot syndrome, diarrhea, and dermatitis. In recent years, hypertriglyceridemia has been reported in patients treated with capecitabine. Dyslipidemia is a rare but important side effect of capecitabine. The aim of this study is to examine the changes in lipid levels during capecitabine treatment and to raise awareness of pharmacovigilance.